IGF::OT::IGF ESTABLISHMENT OF CANCER CELL LINES FOR ADVANCING OVARIAN CANCER HEALTH DISPARITY RESEARCH

卵巢癌(OC)在疾病的所有阶段，从表现到治疗，对非裔美国人(AA)背景的女性都有不成比例的影响。最令人沮丧的事实是，再障患者的死亡率更高，与高加索美国人(CA)相比，他们的存活率不断下降。由于缺乏合适的细胞系模型，成功地理解和描述现有种族差异所涉及的机制在很大程度上受到了阻碍。因此，SBIR第一阶段提案的具体目标是标准化开发新的卵巢癌细胞系的程序和协作设置，以促进OC健康差异的研究。这将通过两个部分实现：(A)从再生障碍性贫血患者的新鲜切除的肿瘤/腹水中建立卵巢癌和成纤维细胞的体外实验模型；(B)通过同工酶图谱、核型分析、短串联重复图谱和突变分析来表征新开发的细胞的基因特征。此外，我们还将对开发的细胞系的典型形态、生长速度(群体倍增时间)、致瘤和转移潜力以及药物敏感性进行表征。拟议研究的成功完成将为建立新的OC细胞系模型建立一个标准化的方案，从而为我们的下一步，即第二阶段，开发多达50个来自AA背景的患者的细胞系模型以及遗传混合物奠定坚实的基础。

Ovarian cancer (OC) disproportionately affects the women of African American (AA) background at all stages of the disease, from presentation through treatment. Most upsetting fact is that AA patients have greater mortality, and their survival rates are continuously decreasing as compared to Caucasian American (CA). Success in understanding and characterizing the involved mechanisms in existing racial disparity is greatly hampered by the lack of suitable cell line models. Therefore, our specific objective of this SBIR Phase I proposal is to standardize the procedure and collaborative set-up for developing novel ovarian cancer cell lines to advance OC health disparity research. This will be achieved in two parts: (A) development of in vitro cell line experimental model of ovarian cancer and fibroblast cells from freshly-resected tumors/ascites fluid of AA patients; (B) Genetic characterization of newly developed cells by isoenzyme profiling, Karyotyping, short-tandem-repeat profiling and mutational analysis. Moreover, we will characterize the developed cell line for typical morphology, growth rates (population doubling time), tumorigenic and metastatic potential and drug sensitivities. Successful completion of the proposed research would establish a standardized protocol for generation of novel cell line models of OC and thus provide a strong foundation for our next step i.e. Phase II for developing up to 50 cell line models from patients of AA backgrounds as well as genetic admixtures.